Abstract Details
|
Keith Van Haren, MD
(Stanford Univ Neurology)
PRESENTER |
Dr. Van Haren has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Viking Therapeutics. Dr. Van Haren has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bluebirdbio. Dr. Van Haren has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Orpheris. Dr. Van Haren has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Autobahn. Dr. Van Haren has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for PRIME, Inc. The institution of Dr. Van Haren has received research support from Minoryx. The institution of Dr. Van Haren has received research support from bluebirdbio. Dr. Van Haren has a non-compensated relationship as a Board of Directors with ALD Connect that is relevant to AAN interests or activities. Dr. Van Haren has a non-compensated relationship as a Scientific Advisory Board with United Leukodystrophy Foundation that is relevant to AAN interests or activities. |
| Tomas Kalincik | Tomas Kalincik has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi Genzyme. Tomas Kalincik has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Tomas Kalincik has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Merck. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Tomas Kalincik has received personal compensation in the range of $500-$4,999 for serving as a Consultant for National Health and Medical Research Council. Tomas Kalincik has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MS Research Australia. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi Genzyme. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Tomas Kalincik has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Tomas Kalincik has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen. Tomas Kalincik has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squibb. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for WebMD Global. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Novartis. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Sanofi Genzyme. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Teva. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for BioCSL. Tomas Kalincik has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Merck. Tomas Kalincik has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eisai. The institution of Tomas Kalincik has received research support from Biogen. The institution of Tomas Kalincik has received research support from Novartis. The institution of Tomas Kalincik has received research support from Genzyme. The institution of Tomas Kalincik has received research support from Roche. The institution of Tomas Kalincik has received research support from Celgene. The institution of Tomas Kalincik has received research support from Merck. The institution of Tomas Kalincik has received research support from MSBase Foundation. The institution of Tomas Kalincik has received research support from ARSEP and EDMUS Foundations. The institution of Tomas Kalincik has received research support from MS Research Australia. The institution of Tomas Kalincik has received research support from National Health and Medical Research Council. The institution of Tomas Kalincik has received research support from Australian Research Council. The institution of Tomas Kalincik has received research support from MS Society. The institution of Tomas Kalincik has received research support from Trish Foundation. Tomas Kalincik has a non-compensated relationship as a scientific leadership group chair with MSBase Foundation that is relevant to AAN interests or activities. |
| Florian Eichler, MD (Massachusetts General Hospital) | An immediate family member of Dr. Eichler has received personal compensation for serving as an employee of UpToDate. Dr. Eichler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Atlas Venture. Dr. Eichler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acadia Pharmaceuticals. Dr. Eichler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Leal Therapeutics. Dr. Eichler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Orchard Tx. Dr. Eichler has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ionis Therapeutics. The institution of Dr. Eichler has received research support from ASPA Therapeutics. The institution of Dr. Eichler has received research support from Abbvie. The institution of Dr. Eichler has received research support from Ionis Pharmaceuticals. |
| Ben Lenail | No disclosure on file |
| No disclosure on file | |
| Kathleen M. Zackowski, PhD, OTR (National MS Society) | Dr. Zackowski has received personal compensation for serving as an employee of National MS Society. |
| Gerald Raymond, MD (Johns Hopkins) | Dr. Raymond has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Bluebird bio. Dr. Raymond has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ionis. Dr. Raymond has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Travere. Dr. Raymond has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant with Dept of HHS. |
| No disclosure on file | |
| No disclosure on file | |
| Joshua Bonkowsky, MD, PhD | Dr. Bonkowsky has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Denali. Dr. Bonkowsky has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurogene. Dr. Bonkowsky has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Passage Bio. Dr. Bonkowsky has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Autobahn. Dr. Bonkowsky has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Bonkowsky has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ionis. Dr. Bonkowsky has stock in Orchard. The institution of Dr. Bonkowsky has received research support from NIH. The institution of Dr. Bonkowsky has received research support from ELA. An immediate family member of Dr. Bonkowsky has received intellectual property interests from a discovery or technology relating to health care. Dr. Bonkowsky has received publishing royalties from a publication relating to health care. Dr. Bonkowsky has received publishing royalties from a publication relating to health care. |
| Robert H. Brown, Jr., MD, DPhil (Univ of Massachusetts Medical School) | Dr. Brown has received personal compensation for serving as an employee of ApicBio. Dr. Brown has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for ApicBio. Dr. Brown has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Warren Alpert Foundation. Dr. Brown has stock in ApicBio. Dr. Brown has stock in Amylx. Dr. Brown has stock in Imstar. The institution of Dr. Brown has received research support from Angel Fund for ALS Research. The institution of Dr. Brown has received research support from ALS Association. The institution of Dr. Brown has received research support from ALSOne. The institution of Dr. Brown has received research support from NINDS. The institution of Dr. Brown has received research support from ALS Finding A Cure. Dr. Brown has received publishing royalties from a publication relating to health care. |
| John K. Fink, MD | No disclosure on file |
| No disclosure on file | |
| Rachel Salzman, DVM (The Stop ALD Foundation) | No disclosure on file |
| Alexander Sherman (Massachusetts General Hospital) | The institution of Mr. Sherman has received research support from The ALS Association. The institution of Mr. Sherman has received research support from NIH. The institution of Mr. Sherman has received research support from FDA. The institution of Mr. Sherman has received research support from Biogen. The institution of Mr. Sherman has received research support from Amylyx Pharmaceuticals. The institution of Mr. Sherman has received research support from Mitsubishi-Tanabe Pharma America. Mr. Sherman has a non-compensated relationship as a Member, Board of Directors with ALD Connect that is relevant to AAN interests or activities. |